



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Nitrosoglutathione

Cat. No.:	HY-D0845		
CAS No.:	57564-91-7		
Molecular Formula:	C <sub>10</sub> H <sub>16</sub> N <sub>4</sub> O <sub>7</sub> S		
Molecular Weight:	336.32		
Target:	Angiotensin Receptor		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 25 mg/mL (74.33 mM; ultrasonic and warming and heat to 60°C)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.9734 mL	14.8668 mL	29.7336 mL
	5 mM	0.5947 mL	2.9734 mL	5.9467 mL
	10 mM	0.2973 mL	1.4867 mL	2.9734 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Nitrosoglutathione (GSNO), a exogenous NO donor and a substrate for rat alcohol dehydrogenase class III isoenzyme, inhibits cerebrovascular angiotensin II-dependent and -independent AT1 receptor responses<sup>[1][2][3][4]</sup>.

#### In Vitro

Nitrosoglutathione (GSNO, 250 μM) prevents 90% of the response to 0.1 μM 5-HT and 40% of the response to 1.0 μM 5-HT in rings treated with LY-83583, indicating an effect of GSNO that was independent of guanylate cyclase activity<sup>[5]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

Nitrosoglutathione (GSNO, 8 mg/kg) significantly decreases systolic, diastolic, and mean arterial pressures in PE-induced rats from day 14 through day 20<sup>[3]</sup>. Nitrosoglutathione (GSNO, 0.2 and 0.6 mg/kg) significantly inhibits superoxide production and suppressed NF-κB activation, iNOS induction, and 3-nitrotyrosine expression, but up-regulates endothelial NOS expression in the flap vessels<sup>[4]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Lewis rats<sup>[4]</sup>.

---

Dosage:	0.2 and 0.6 mg/kg.
Administration:	Slow intravenous injection via the opposite femoral vein into each rat.
Result:	Animals treated with 0.2 mg of GSNO per kilogram before reperfusion had an intermediate survival rate (40.2 ± 4.9%). Although 0.6 mg/kg of GSNO showed a better rescuing effect than 150 mg/kg of NAC, there was no significant difference between the groups.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA